---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-126489"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2022-12-13T23:59:59+00:00"
generated_at: "2026-06-21T05:39:31.343644+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Priveterra (PMGM) enters definitive merger with AEON Biopharma at $165M equity value

## Summary
- Implied AEON equity value of $165M; AEON stockholders to receive Priveterra Class A common shares.
- Up to 16M earnout shares tied to FDA milestones: Phase 3 migraine start, BLA acceptance for cervical dystonia and migraine.
- Bridge financing: up to $20M from AEON stockholders; $4M bridge if Closing not by March 1, 2023; $8M sponsor bridge if S-4 not effective by April 1, 2023.
- Closing condition: minimum $45M available cash after redemptions, stockholder approvals, Nasdaq listing, and HSR clearance.
- Sponsor (3.45M Contingent Founder Shares) and AEON stockholders subject to 1-year lock-up; early release at $12.50/$15.00 VWAP thresholds.

## SEC filing metadata
- accession: 0001104659-22-126489
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2022-12-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000110465922126489/0001104659-22-126489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000110465922126489/tm2232428d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-126489
- JSON: https://secwatch.observer/filing/0001104659-22-126489.json
- Plain text: https://secwatch.observer/filing/0001104659-22-126489.txt

## Key facts
- Material Agreements
  AEON Biopharma, Inc. entered into Business Combination Agreement with AEON Biopharma, Inc. valued at implied AEON equity value of $165,000,000, plus up to 16,000,000 earnout shares of Class A common st (effective 2022-12-12).
  - Action: entry
  - Agreement: merger
  - Counterparty: AEON Biopharma, Inc.
  - Value: implied AEON equity value of $165,000,000, plus up to 16,000,000 earnout shares of Class A common st
  - Effective: 2022-12-12
  source text: On December 12, 2022, Priveterra Acquisition Corp., a Delaware corporation (the “ Company ” or “ Priveterra ”), entered into a business combination agreement (the “ Business Combination Agreement ”) by and among the Company, Priveterra Merger Sub, Inc., a Delaware corporation (“ Merger Sub ”), and AEON Biopharma, Inc., a Delaware corporation (“ AEON ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000110465922126489/0001104659-22-126489-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.